Villi stromal cells compositions and uses thereof
OwnerRamon CORONADOinventor
Life of this patent
Estimating the term…
Abstract
The invention provides compositions of perinatal stromal cells and methods of use thereof. Specifically, the invention provides composition comprising amniotic stromal cells, Wharton's jelly stromal cells, placenta proper stromal cell, chorionic stromal cells, or chorionic villi stromal cells; and methods of uses thereof for the treatment of graft versus host disease, for reducing fibrosis, for reducing inflammation, for inducing immune tolerance, and for treating single- or multi-organ fibrosis.
Claims38
A perinatal stromal cell (PSC) composition comprising at least one of the following cell types:
- (i) amnion perinatal stromal cells (APSCs), (ii) placenta proper stromal cells (PPSCs), (iii) Wharton's jelly perinatal stromal cells (WPSCs), (iv) whole chorion derived stromal cells (CSCs), and (v) chorionic villi-derived stromal cells (CVCs), and a pharmaceutically acceptable carrier.
The PSC composition of any one of the foregoing claims, wherein at least one of the APSCs, PPSCs, WPSC, or CVCs express a molecular marker selected from the group consisting of CD105, CD90, CD73, CD273, CD210, and a combination thereof.
The PSC composition of any one of the foregoing claims, wherein at least one of the APSCs, PPSCs, WPSCs, or CVCs does not express a molecular marker selected from the group consisting of CD11b, CD45, HLADR, CD119, CD85b, CD178, CD40, and a combination thereof.
The PSC composition of any one of the foregoing claims, wherein said cells are derived from more than one donor.
The PSC composition of any one of the foregoing claims, wherein said cells are derived from more than one donor of the same blood type.
The PSC composition of any one of the foregoing claims, wherein said cells are derived from more than one donor which have been determined to be histocompatible with each other.
The PSC composition of any one of the foregoing claims, wherein said cells are derived from more than one donor which have been determined to comprise the same or comprise similar human leukocyte antigens (HLA) alleles or major histocompatibility complex (MHC).
The PSC composition of any one of the foregoing claims, wherein said cells are derived from one or more donors wherein the DNA thereof has been analyzed to confirm that the cells do not comprise gene mutations including those correlated to genetic diseases including but not limited to cancer, Autosomal dominant diseases such as familial hypercholesterolemia, Neurofibromatosis type I, Hereditary spherocytosis, Marfan syndrome, Huntington's disease, Autosomal recessive diseases such as Sickle cell anemia, Cystic fibrosis, Tay-Sachs disease, Phenylketonuria, Autosomal recessive polycystic kidney disease, Mucopolysaccharidoses, Lysosomal acid lipase deficiency, Glycogen storage diseases such as Galactosemia, X-linked diseases such as Duchenne muscular dystrophy, and Hemophilia.
The PSC composition of any one of the foregoing claims, wherein said cells are derived from one or more donors which have been determined not to comprise any pathogenic viruses or other microbial pathogens.
A method of reducing chronic inflammation and consequent tissue fibrosis in a subject comprising administering to the subject in need thereof the perinatal stromal cell (PSC) composition of any one of the foregoing claims.
A method of treating or preventing fibrosis in a subject in need thereof comprising administering to the subject in need thereof the perinatal stromal cell (PSC) composition of any one of the foregoing claims.
Dependencies are inferred from the claim text.